EVO Evotec SE
USHealthcareAs of 2026-07-10 16:00
Why EVO matters now
Evotec SE (EVO) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.79 with -1.94% on the session and $989.2M in market capitalization; recent performance reads 1-month -7.91% and YTD -16.88%.
The latest financial table shown here is Q1 2026, with revenue of $159.2M, net income of $-123.9M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.2%.
The latest indexable market news headline is "Evommune's Healthy Balance Sheet Buys Them Time For AD" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.18
P/S
1.10
EV/EBITDA
-21.29
DCF Value
$-3.47
FCF Yield
-5.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
11.5%
Operating Margin
-13.9%
Net Margin
-26.0%
ROE
-24.5%
ROA
-11.8%
ROIC
-7.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $159.2M | $-123.9M | $-0.35 |
| Q4 2025 | $250.9M | $14.5M | $0.04 |
| FY 2025 | $757.3M | $-99.4M | $-0.28 |
| Q3 2025 | $163.9M | $-43.1M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
DE
Exchange
—
Beta
1.30
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.